Some follow the noise.

Bloomberg follows the money, whether it's the funds fueling AI or crypto's trillion-dollar swings.

There's a money-side to every story.

Get the money-side of the story.

Subscribe now at Bloomberg.com.

So most things have not gone very far, but they do illustrate that infections happen.

Transmission can happen as it did with SARS, with one of the SARS releases by mistake in the mid-2000s.

So it is a real risk.

And now the Good Fight with Yasha Monk.

Around the world, there have been, and to some extent still are a lot of labs that engage in gain-off function research.

What that means is that they take a pathogen and they try to find

all the ways in which it could be more dangerous. Now, the purpose of this is to make sure

that we are prepared for all kinds of possibilities that we can prevent terrible pandemics in

the future. But there's also an obvious risk. What if one of these pathogens that leaks from

the lab? What if somebody working in those labs

learns how to do them and replicates it for nefarious purposes of the own? There's all kinds of

things that could go wrong. Arguably, that is what did go wrong at the beginning of the COVID

pandemic. So should we ban gain of function research? Well, today I invited into my

podcast somebody who has argued that we should at the very least be much, much more cautious

about gain of function research than we are. And he is a very senior figure in the field of

public health. Mark Lipsich has taught at Harvard for a long time,

just joined the Stanford faculty,

...